Abstract: Recombinant human growth hormone (rhGH) has been widely used in many medical applications. Large scale production of rhGH is important for a wider application of this molecule in the field of proteomics. This investigation reports a modified Agrobacterium-mediated method for transfer and expression of human growth hormone gene in the popular edible mushroom Pleurotus eryngii. A binary vector pCAMBIA1304 containing the hGH2 gene was constructed and introduced into Pleurotus eryngii via Agrobacterium tumefaciens-mediated transformation. Integration of hGH2 into mushroom genome was detected by PCR and expression was confirmed by Western blot assay. The successful expression of the human growth hormone gene in mushroom suggests that the proposed modified transformation system is probably useful for the production of transgenic mushrooms.
Introduction
The advent of recombinant protein production technology has led to a worldwide zeal for the development of protein pharmaceuticals in the past two decades. These protein pharmaceuticals or pharmaceutical candidates include functional regulators and supplements, enzyme activators and inhibitors, polyclonal and monoclonal antibodies, and various vaccines. In comparison with small chemical drugs, protein pharmaceuticals have high specificity and activity at relatively low concentrations. These features have made protein pharmaceuticals indispensable for combating human diseases.
Human growth hormone (hGH) is an endocrine hormone produced and secreted by the somatotrophic cells of the anterior pituitary. hGH has been available over 40 years for the treatment of children with GH deficiency. The most prominent effects of GH include promoting growth and inducing protein anabolic and lipolytic pathways. Aside from its growth stimulation effects, hGH has been considered as a possible therapeutic agent for the treatment of the frailty associated with aging, osteoporosis, morbid obesity, cardiac failure, major thermal injury, and a variety of other acute and chronic catabolic conditions [1] . It has been shown to of considerable benefit to girls with Turner syndrome, children with chronic renal failure, and adults with growth hormone deficiency or human immunodeficiency virus (HIV) syndrome [2] . Recombinant human growth hormone (rhGH) is anabolic and enhances immune functions [3] [4] [5] [6] . It has been clinically used in many situations such as organ transplantation [7] , major trauma [8] , and severe burns [9] .
Production of value-added exogenous proteins by recombinant DNA technology is one of the most important areas in the research and development of modern biotechnology. Recombinant protein expression systems have been developed in microorganisms, mammals, plants, and insects for use in the production of desired foreign proteins. Although there is no universal host system for the expression of all foreign proteins [10] , it is necessary to develop more types of foreign gene expression systems for the expression of a greater variety of more high-value proteins. Fungi play important roles in many human activities, including biotechnological processes, phytopathology, and biomedical research. They form part of the diet in many countries due to their flavorful taste and nutritive value. They are attractive hosts for recombinant DNA technology because of their ability to secrete high levels of bioactive proteins with post-translational processing such as glycosylation. Pleurotus eryngii, also called the king oyster mushroom, is one of the most famous and popular edible mushrooms in Asia, Europe and North America [11] . The increasing popularity of P. eryngii among consumers is due to its flavor, texture, and shelf life [12] . Commercial production of this mushroom began in Italy in the mid 1970s and is now produced in over a dozen other countries. As a higher eukaryotic organism it possesses the complete protein-translational modification; therefore it is good model organism for exogenous gene expression and has great potential to produce pharmaceutical proteins.
The Agrobacterium tumefaciens-mediated transformation system described for the yeast Saccharomyces cerevisiae [13, 14] was first reported in fungi in 1998 [15] . Further developments in Agrobacterium tumefaciens-mediated transformation of fungi have been reported [16] and several studies continued to optimize the technology. In the present study, we introduced for the first time the hGH2 gene into the edible mushroom Pleurotus eryngii, using Agrobacterium-mediated transformation, which resulted in a successful expression of the human gene. We also suggest a modified Agrobacterium-mediated method for the efficient transformation of hGH2 in Pleurotus eryngii.
Experimental Procedures

Strains and gene
Escherichia coli strain DH5α (Invitrogen, USA) was used for the propagation of plasmids. pDNR-LIB vector containing hGH2 gene was purchased from 21C Frontier Human Gene Bank (KRIBB, Korea). pCAMBIA1304 was obtained from BioForge, USA. Agrobacterium tumafaciens GV3101 was provided by NEXGEN, Biotechnologies, Inc. Korea. Pleurotus eryngii was obtained from Rural Development Administration (RDA), Republic of Korea.
Construction of binary vector harboring the hGH2 gene
To construct a binary vector, plasmids pCAMBIA1304 ( Figure 1A ) and pDNR-LIB (hGH2) ( Figure 1B) were digested with EcoRI and HindIII and the hGH2 gene was inserted into pCAMBIA1304 in these same restrictionenzyme sites. The resulting plasmid was designated pCAMBIA1304(hGH2) ( Figure 1C 
Transformation of Agrobacterium
For Agrobacterium transformation 500 μl of the GV3101 strain of Agrobacterium tumefaciens was transferred to 50 ml of LB (Luria-Bertani) medium (1% bacto-tryptone, 0.5% bacto-yeast extract, and 1% NaCl, pH 7.0), and grown overnight at 28°C. Bacteria were collected by centrifugation and suspended in 20 mM CaCl 2 . The recombinant plasmid pCAMBIA1304(hGH2) was introduced into Agrobacterium by freeze-thaw method. The positive colonies can grow on LB medium plates containing 50 μg/ml kanamycin. The positive colonies were confirmed by PCR using the primers described above. Each 20 μl PCR reaction contained 10 pM of the each primer, 1×PCR buffer, 2.5 mM dNTPs, 1 unit Taq DNA polymerase (TaKara, Kyoto, Japan), and 1 μl of each transformant lysate as the template. PCR was performed by denaturing at 94°C for 5 min, followed by 35 cycles of amplification (94°C for 1 min, 58.2°C for 1 min and 72°C for 4 min), and final extension at 72°C for 7 min. PCR products were analyzed on 1% agarose gel and visualized by ethidium bromide (EtBr).
Transformation by vacuum infiltration
Agrobacterium tumefaciens (GV3101) cells carrying the plasmid pCAMBIA1304(hGH2) were grown in 50 mL LB medium supplemented with kanamycin (50 μg/ml) at 28°C for 2 days to OD 600 =1.6. Bacteria were collected by centrifugation for 30 min at 4000×g and then washed once with 50 ml washing solution containing 10 mM MgCl 2 and 100 μM acetosyringone. After centrifugation at 4000×g for another 30 min, pellet of bacteria was resuspended in washing solution to OD 600 =1.0. The veil was cut from the fruiting body of Pleurotus eryngii and the exposed gill tissue was excised aseptically and sectioned into 1.0×0.5 cm pieces. These pieces were vacuum infiltrated with the suspension of induced bacteria twice for 10 min each time. The evacuated tissues were washed three times with distilled water and dry on sterile Whatman filter paper under aseptic condition for 10 min. The tissues were then transferred to a sterile Petri dish without medium and incubated for 7-14 days in darkness at 25°C. For selection, the dark cultured active tissues were transferred to PDA medium (20% potato extract, 2% dextrose, and 1.5% agar) containing 50 μg/ml hygromycin and 100 μg/ml cefotaxime and cultured for 2-3 weeks in dark condition at 25°C. This dark culture method is highly effective for growing mycelia and eliminating Agrobacterium. Putative transformants were then subcultured onto PDA medium without hygromycin at 25°C for one week in dark. Finally, the mycelia were subcultured on liquid medium containing PDB for two weeks in shaking incubator at 25°C at 130 rpm. Mycelia were then separated by filtration through Whatman filter paper and used for further processing.
GUS histochemical assay
The pieces of transformed and untransformed mushroom were incubated in cold 90% acetone on ice for 15 min. The acetone was removed and washed the samples by rinse solution (50 mM sodium phosphate buffer (pH 7.2), 0.5 mM potassium ferrocyanide, 0.5 mM potassium ferricyanide). After removing the rinse solution from samples, staining solution (50 mM sodium phosphate buffer (pH 7.2), 0.5 mM potassium ferrocyanide, 0.5 mM potassium ferricyanide, and 2 mM X-Gluc) was added to the samples which were maintained on ice. The samples were then subjected to vacuum infiltration on ice for 15 min. The vacuum treatment was repeated two times. The samples were incubated at 37°C at room temperature and then photographed.
PCR analysis of target gene in transgenic mushroom
PCR was performed to determine whether the hGH2 gene had been integrated into the mushroom genome. Genomic DNA was extracted from putative transgenic mushrooms and control untransformed mushrooms. For genomic DNA isolation, the mushroom samples were ground to a fine powder in liquid nitrogen. Then, 700 μl of lysis buffer (100 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 10% SDS, 1 μg RNase A) was added and mixed thoroughly. The samples were incubated at 65°C for 20 min, after which they were centrifuged at 13,000×g for 5 min at 4°C. The supernatant was transferred to fresh tubes. An equal volume of isopropanol was added to each sample, mixed well, and samples were centrifuged for 10 min, 4°C at 13000×g. The pellet was washed with 70% ethanol, dried, and then resuspended in 20 μl sterile distilled water. DNA samples were subjected to PCR amplification using the primers and conditions described above. PCR products were electrophoresed in 1% agarose gels with EtBr in 1× TAE buffer and then photographed.
Western blot analysis
Mycelia were collected and subsequently ground in liquid nitrogen with a mortar and pestle. A total of 50 mg mycelia powder was mixed with 1 ml protein extraction buffer (50 mM sodium phosphate, pH 7.4, 1 mM EDTA, 0.1% Triton X-100, 150 mM NaCl, 6 M urea and 0.3 M guanidine hydrochloride) on ice for 5 min. Following centrifuging at 13,000×g for 20 min, the supernatant containing total cellular protein was transferred to a fresh tube. The protein concentration of the putative transgenic mushroom or untransformed mushroom samples was determined using a BCA (bicinchoninic acid) protein assay kit (Pierce Co.). Protein extract (20 μg from each sample) was separated by SDS-polyacrylamide gel electrophoresis and then transferred to a polyvinylidene fluoride (PVDF) membrane. After the completion of the transformation the membrane was blocked for 3 h with 3% bovine serum albumin (BSA) in TBS containing 0.05% Tween-20 (TBST) on ice to avoid non-specific binding of the antibody. Monoclonal primary antibody, mouse anti-human growth hormone (mAHuGH; ProSpec-Tany Technogene), was diluted 1:1000 in TBST solution and incubated overnight on ice. The membrane was then washed 3 x 10 min with TBST followed by a 3 h room-temperature incubation with horseradish peroxidase-labelled goat anti-mouse IgG antibody (Santa Cruz, USA) which was diluted 1:1000 in TBST. After washing 3 x 15 min with TBST, the bound antibody was localized using the WestZol (Plus) Western blot detection system (Intron Biotechnology Inc, Korea) and captured on X-ray film (Kodak, USA).
Results
Expression vector construction and generation of transgenic mushroom carrying the rhGH2
The binary vector, pCAMBIA1304 was used for the initial transformation. A 314 bp fragment of the hGH2 gene was inserted into pCAMBIA1304. The target gene was confirmed via restriction enzyme digestion ( Figure 2A ) and PCR ( Figure 2B ), both of which produced bands of the expected size. The DNA sequence of the cloned gene was found to be identical to the reported gene sequence. pCAMBIA1304(hGH2) was then introduced into A. tumefaciens. The positive colonies were tested for the presence of hGH2 by PCR analysis with hGH2, pCAMBIA1304 as described in the Experimental Procedures section. PCR results are shown in Figure 2C . The result showed that A. tumefaciens contained the hGH2 insert. The resultant plasmid pCAMBIA1304(hGH2) was subsequently introduced into fruiting bodies of P. eryngii using Agrobacterium tumefaciens strain GV3101-mediated transformation by vacuum infiltration. After cultivation of infiltrated samples in darkness for 7-14 days, a histochemical GUS assay was carried out. Accumulation of GUS enzyme was not detected in non-transformed control samples. The samples transformed with A. tumefaciens were shown to express high levels of GUS activity ( Figure 3A) . Following the dark culture, the tissues infected with Agrobacterium were placed on the selection media containing antibiotics (50 μg/ml hygromycin and 100 μg/ml cefotaxime). Hygromycin-resistant colonies appeared at the margins of the tissue pieces after 2-3 weeks on PDA medium with hygromycin at 50 μg/ml ( Figure 3B ).
The mycelia were grown rapidly from the putative transformants whereas mycelia were not grown from non-transformed tissues. Our procedure yielded 65-75% efficiency of transformation, which is higher than previous reported transformation methods in mushroom. After final selection with hygromycin, we typically maintained a stable hygromycin-resistant culture for weeks to months on a PDA medium without hygromycin (Figure 4) . After sub-cultured on PDB medium, we obtained the putative transgenic mycelium for further analysis. , PCR analysis of the hGH2 from transformed E. coli using the primer combination. M, 100 bp marker; lane 1, control (hGH2) using primer F2, R2; lane 2, transformed DNA using primer F1, R2; lane 3, transformed DNA using primer F2, R2; lane 4, transformed DNA using primer F2, R1; lane 5, transformed DNA using primer F1, R1; lane 6, pCAMBIA1304 without hGH2 using primer F1, R1. (C), PCR detection of the hGH2 from transformed A. tumefaciens GV3101 using the primer combination. M, 100 bp marker; lane 1, control (hGH2) using primer F2, R2; lane 2, transformed DNA using primer F1, R2; lane 3, transformed DNA using primer F2, R2; lane 4, transformed DNA using primer F2, R1; lane 5, transformed DNA using primer F1, R1. 
Detection of hGH2 gene integration in transformed mushroom
To confirm integration of hGH2 genes, PCR was performed using genomic DNA template isolated from transgenic mushrooms. The products of this PCR amplification are shown in Figure 5A . The expected PCR product was a 314 bp hGH2, which is the size of the PCR-amplified DNA fragment. No band was observed using genomic DNA template from the non-transformed mushroom samples.
Expression of the hGH2 in transgenic mushroom
To investigate the expression of the hGH2 in transgenic mushroom, Western blot analysis was carried out using hGH2-specific monoclonal primary antibody. Total protein was extracted from the non-transformed and transformed mushroom was electrophoretically resolved on a 12% SDS-PAGE gel and then transferred to a PVDF membrane for immunoblotting. The samples were found to express hGH2 proteins with identical molecular weight. The results showed that a molecular weight of 22 kDa specific band was observed in transgenic mushroom samples, whereas this band was absent from untransformed mushroom ( Figure 5B ). This result confirmed that the hGH2 in mushroom cells was correctly translated.
Discussion
In this study, we investigated the mushroom as a potential system for the therapeutic protein production by examining the expression of human gene in the P. eryngii. Fungi are robust industrial fermentation organisms for the expression of therapeutic proteins as compared to other eukaryotic expression systems like baculovirus and mammalian cells. Recently, mushrooms have become organisms of choice for applications in biotechnology. Mushrooms offer several advantages over animal and plant production systems, including increased secretion, easy molecular and genetic manipulation, lack of endotoxins, stable storage, and economical marketing [17] [18] [19] . Basidiomycete mushrooms have not been considered as a platform for the production of therapeutic proteins until now [20] . Previously, several other expression system such as Bacillus subtilis [21] , Escherichia coli [22] , Pichia pastoris [23] , transgenic mice [24] , and transgenic goat [25] have been used for producing hGH. This is the first report to express hGH in P. eryngii by the Agrobacterium-mediated transformation system, and we have demonstrated that it was feasible to express a pharmaceutically important gene in mushroom. Although, the biological activity of rhGH2 has yet to be established, immunoblot assay revealed a specific band with expected molecular weight, indicating that the hGH2 in mushroom was translated correctly. The attractiveness of mushrooms, including the basidiomycetes, as production hosts is based on their natural ability to secrete large amounts of bioactive proteins with correct posttranslational processing, such as glycosylation [18] [19] [20] . Interestingly, the simple oligomannosidic N-glycosylation in the basidiomycetes favors the reproducible production of a homogeneous and human-like glycosylated protein product [20] . N-glycosylation has both a function in proper protein folding and in endoplasmic reticulumdependent degradation of misfolded proteins. Moreover, it determines the biochemical and biophysical properties of a protein as well as its immunogenicity and, often, its bioactivity [26] .
Until now, there was no available method for the efficient transformation of human gene into mushroom using Agrobacterium; pioneering efforts were made by De Groot et al. [15] and Chen et al. [16] for Agrobacterium-mediated transformation of fungi. In this study, we explored a different approach to transform human gene into P. eryngii mediated by Agrobacterium. An overview of the modified Agrobacterium-mediated transformation system is shown in Figure 6 . Our results suggest that incubation of bacterial suspension prior to vacuum infiltration is not necessary. Similarly, we avoid the incubation of evacuated tissues on filter paper for 3 days as described by Chen et al., [16] and instead dry the samples on filter paper under aseptic conditions for 10 min. Our study also suggests that incubation for 7-14 days in darkness in a Petri dish without medium produces favorable results and has following advantages: (1) bacteria are killed, (2) transformation efficiency is increased, and (3) the samples adapt quickly in selection media. However, various parameters such as nature of fungal starting material, the Agrobacterium strain, and selection of co-cultivation conditions affect the transformation frequency [16, 27] . Vacuum infiltration is an important factor in the success of this protocol, which led to a very high number of bacteria becoming evenly distributed in the intercellular spaces. Prolonged exposure to the vacuum, however, rapidly decreased the temperature of the suspension of Agrobacterium, which may have caused reduced levels of expression [28] . In our hands, a two 10 min vacuum infiltrations were found to be optimal. Our transformation system rendered 65-75% efficiency, which is higher than reported previously [16] . It is important to note, however, that each type of fungus has its own set of optimal conditions that are needed to maximize transformation frequencies [27] .
In conclusion, we have engineered expression of the hGH gene in edible mushroom. The data on A. tumefaciens-mediated transformation of hGH presented here provides a reliable, easy, and economical procedure for the development of transgenic mushroom as well as transformation techniques for mushroom that can be used as a production host for other human therapeutic proteins. Through the expression of recombinant human proteins in mushroom, this work could contribute substantially to the development of cures for disease as well as the maintenance and promotion of good health. Figure 6 . Overview of the Agrobacterium-mediated transformation system for human gene in mushroom.
